ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

PHOTOFRIN
Colorectal and other GI cancers
Respiratory and thoracic cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

PHOTOFRIN Rx

Generic Name and Formulations:
Porfimer (as sodium) 75mg/vial; pwd for IV inj after reconstitution; preservative-free.

Company:
Pinnacle Biologics

Therapeutic Use:

Indications for PHOTOFRIN:

Palliation of patients with completely obstructing esophageal cancer or partially obstructing esophageal cancer who cannot be satisfactorily treated with Nd:YAG laser therapy. Ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy.

Adult:

See literature. Give by slow IV inj over 3–5 minutes. 2mg/kg then illumination with laser light 40–50 hours following injection. Esophageal cancer: 2nd course may be given at a minimum of 30 days after initial therapy; max 3 courses (separated by ≥30 days). Ablation of high-grade dysplasia in Barrett's esophagus: 2nd course may be given at a minimum of 90 days after initial therapy; max 3 courses (separated by ≥90 days).

Children:

Not recommended.

Pharmacological Class:

Photosensitizing agent.

Contraindications:

Porphyria. Existing tracheoesophageal or bronchoesophageal fistula. Tumors eroding into a major blood vessel. Emergency treatment of patients with severe acute respiratory distress caused by an obstructing endobronchial lesion. Esophageal or gastric varices. Esophageal ulcers >1cm in diameter.

Warnings/Precautions:

Avoid direct sunlight or bright indoor light; wear dark sunglasses when outdoors. Increased risk of fatal massive hemoptysis with large, centrally located tumors, cavitating tumors, extensive tumor extrinsic to the bronchus. Caution with endobronchial tumors in locations where treatment-induced inflammation could obstruct airway. Avoid extravasation. Pregnancy (Cat.C; use adequate contraception), nursing mothers: not recommended.

Interactions:

Increased risk of photosensitivity reactions with other photosensitizing agents (eg, tetracyclines, sulfonamides, phenothiazines, sulfonylurea hypoglycemic agents, thiazide diuretics, griseofulvin, fluoroquinolones). May be antagonized by dimethyl sulfoxide, β-carotene, ethanol, formate, mannitol, allopurinol, calcium channel blockers, prostaglandin synthesis inhibitors, drugs that decreased clotting, vasoconstriction or platelet aggregation (eg, thromboxane A2 inhibitors), glucocorticoid hormones. Separate radiotherapy by 2–4 weeks.

Adverse Reactions:

Photosensitivity reactions (eg, erythema, swelling, itching, burning sensation, feeling hot, blisters), fluid imbalance, chest pain, fever, pain, abdominal pain, GI upset, constipation, mucositis, ocular sensitivity, dyspnea, pleural effusion, anemia, fistula formation, fatal massive hemoptysis, others.

How Supplied:

Vial—1

Indications for PHOTOFRIN:

Reduction of obstruction and palliation in patients with completely or partially obstructing endobronchial non-small-cell lung cancer (NSCLC). Treatment of microinvasive endobronchial NSCLC in patients for whom surgery and radiotherapy is not indicated.

Adult:

See literature. Give by slow IV inj over 3–5 minutes. 2mg/kg then illumination with laser light 40–50 hours following injection. 2nd course may be given at a minimum of 30 days after initial therapy; max 3 courses (separated by ≥30 days).

Children:

Not recommended.

Pharmacological Class:

Photosensitizing agent.

Contraindications:

Porphyria. Existing tracheoesophageal or bronchoesophageal fistula. Tumors eroding into a major blood vessel. Emergency treatment of patients with severe acute respiratory distress caused by an obstructing endobronchial lesion. Esophageal or gastric varices. Esophageal ulcers >1cm in diameter.

Warnings/Precautions:

Avoid direct sunlight or bright indoor light; wear dark sunglasses when outdoors. Increased risk of fatal massive hemoptysis with large, centrally located tumors, cavitating tumors, extensive tumor extrinsic to the bronchus. Caution with endobronchial tumors in locations where treatment-induced inflammation could obstruct airway. Avoid extravasation. Pregnancy (Cat.C; use adequate contraception), nursing mothers: not recommended.

Interactions:

Increased risk of photosensitivity reactions with other photosensitizing agents (eg, tetracyclines, sulfonamides, phenothiazines, sulfonylurea hypoglycemic agents, thiazide diuretics, griseofulvin, fluoroquinolones). May be antagonized by dimethyl sulfoxide, β-carotene, ethanol, formate, mannitol, allopurinol, calcium channel blockers, prostaglandin synthesis inhibitors, drugs that decreased clotting, vasoconstriction or platelet aggregation (eg, thromboxane A2 inhibitors), glucocorticoid hormones. Separate radiotherapy by 2–4 weeks.

Adverse Reactions:

Photosensitivity reactions (eg, erythema, swelling, itching, burning sensation, feeling hot, blisters), fluid imbalance, chest pain, fever, pain, abdominal pain, GI upset, constipation, mucositis, ocular sensitivity, dyspnea, pleural effusion, anemia, fistula formation, fatal massive hemoptysis, others.

How Supplied:

Vial—1

Sign Up for Free e-newsletters